The Directors of Scancell Holdings plc, the parent company of Scancell Limited (‘Scancell’), the developer of therapeutic cancer and infectious disease vaccines based on its patented ImmunoBody® platform, are pleased to announce the preliminary results for Scancell for the year ended 30th April 2009 (‘the Period’).
Highlights:
- Admitted to Plus markets and raised £1.559,502
- Signed deal with Cobra Biomanufacturing Plc to commence Good Manufacturing Practice manufacture of Scancell’s SCIB1 DNA vaccine
- Awarded £250,000 Grant for Research and Development by the East Midlands Development Agency
- Preparations for scheduled 2010 Phase 1 clinical trials of Scancell’s first cancer vaccine for melanoma, SCIB1, continued on time and on budget
- Voted ACQ Magazine Plus Company of the year
Post Period Highlights:
- Merck Serono: signed licensing agreement for two key patents required for further development and commercialisation of protein ImmunoBody® vaccines
- Ichor Medical Systems: agreement signed to use Ichor's TriGrid™ electroporation device for the delivery of SCIB1
- ImmunoVaccine Technologies Inc.: signed a research agreement to explore using IVT’s DepoVax™ delivery system for Scancell’s future ImmunoBody® DNA infectious disease and animal health vaccines
- Zeus Capital appointed as Corporate Advisor
David Evans, Non-Executive Chairman of Scancell, commented:
“I am pleased to report on Scancell’s first successful year as a public company. The Company continues to make good progress towards commencing Phase 1 clinical trials on its first therapeutic cancer vaccine SCIB1 in 2010..Scancell has also entered into a number of significant agreements that will support both SCIB1 and the development of future ImmunoBody® vaccines.”
For further information contact:
Professor Lindy Durrant - Scancell Holdings Plc - +44 207 245 1100
Adam Reynolds/Vikki Krause - Hansard Group - +44 7515 922906
Ross Andrews - Zeus Capital - +44 (0)161 831 1512
View the full results